BIOMAT Database Logo BIOMAT Database Logo

Busulfan triggers epileptic seizures under levetiracetam and valproic acid therapy. 2014

Arzu Yazal Erdem, and Fatih Azık, and Betül Tavil, and Serap Teber, and Bahattin Tunç, and Duygu Uçkan
Department of Pediatric Hematology Oncology, Ankara Pediatric & Pediatric Hematology Oncology Training and Research Hospital, Ankara, Turkey. arzu.erdem@gmail.com.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D010889 Piracetam A compound suggested to be both a nootropic and a neuroprotective agent. 2-Pyrrolidone-N-Acetamide,Avigilen,Axonyl,Cerebroforte,Cerepar N,Ciclofalina,Cuxabrain,Dinagen,Gabacet,Geram,Memo-Puren,Nootrop,Nootropil,Nootropyl,Normabraïn,Piracebral,Piracetam AbZ,Piracetam-RPh,Piracetrop,Pirazetam,Pyracetam,Pyramem,Sinapsan,UCB-6215,Memo Puren,Piracetam RPh,UCB 6215,UCB6215
D002066 Busulfan An alkylating agent having a selective immunosuppressive effect on BONE MARROW. It has been used in the palliative treatment of chronic myeloid leukemia (MYELOID LEUKEMIA, CHRONIC), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen. Busulphan,Busulfan Wellcome,Busulfex,Glyzophrol,Myelosan,Mylecytan,Myleran,Myléran,n-Butane-1,3-di(methylsulfonate),Wellcome, Busulfan
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D004827 Epilepsy A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313) Aura,Awakening Epilepsy,Seizure Disorder,Epilepsy, Cryptogenic,Auras,Cryptogenic Epilepsies,Cryptogenic Epilepsy,Epilepsies,Epilepsies, Cryptogenic,Epilepsy, Awakening,Seizure Disorders
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077287 Levetiracetam A pyrrolidinone and acetamide derivative that is used primarily for the treatment of SEIZURES and some movement disorders, and as a nootropic agent. Etiracetam,Etiracetam, (R)-,Etiracetam, R-isomer,Etiracetam, S-isomer,Keppra,UCB 6474,UCB-6474,Ucb L059,Ucb L060,Ucb-L059,Ucb-L060,alpha-ethyl-2-oxo-1-Pyrrolidineacetamide,Etiracetam, R isomer,Etiracetam, S isomer,R-isomer Etiracetam,S-isomer Etiracetam,UCB6474,UcbL060,alpha ethyl 2 oxo 1 Pyrrolidineacetamide
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000927 Anticonvulsants Drugs used to prevent SEIZURES or reduce their severity. Anticonvulsant,Anticonvulsant Drug,Anticonvulsive Agent,Anticonvulsive Drug,Antiepileptic,Antiepileptic Agent,Antiepileptic Agents,Antiepileptic Drug,Anticonvulsant Drugs,Anticonvulsive Agents,Anticonvulsive Drugs,Antiepileptic Drugs,Antiepileptics,Agent, Anticonvulsive,Agent, Antiepileptic,Agents, Anticonvulsive,Agents, Antiepileptic,Drug, Anticonvulsant,Drug, Anticonvulsive,Drug, Antiepileptic,Drugs, Anticonvulsant,Drugs, Anticonvulsive,Drugs, Antiepileptic

Related Publications

Arzu Yazal Erdem, and Fatih Azık, and Betül Tavil, and Serap Teber, and Bahattin Tunç, and Duygu Uçkan
Nonepileptic seizures under levetiracetam therapy.
November 2010, Epilepsy & behavior : E&B,
Arzu Yazal Erdem, and Fatih Azık, and Betül Tavil, and Serap Teber, and Bahattin Tunç, and Duygu Uçkan
Drug interaction between valproic acid and carbapenems in patients with epileptic seizures.
March 2017, The Kaohsiung journal of medical sciences,
Arzu Yazal Erdem, and Fatih Azık, and Betül Tavil, and Serap Teber, and Bahattin Tunç, and Duygu Uçkan
Concomitant use of clonazepam and valproic acid in treatment of epileptic seizures.
January 1979, American journal of hospital pharmacy,
Arzu Yazal Erdem, and Fatih Azık, and Betül Tavil, and Serap Teber, and Bahattin Tunç, and Duygu Uçkan
Pharmacokinetic interaction on valproic acid and recurrence of epileptic seizures during chemotherapy in an epileptic patient.
May 2005, British journal of clinical pharmacology,
Arzu Yazal Erdem, and Fatih Azık, and Betül Tavil, and Serap Teber, and Bahattin Tunç, and Duygu Uçkan
Valproic acid free fraction in epileptic children under chronic monotherapy.
June 1983, Therapeutic drug monitoring,
Arzu Yazal Erdem, and Fatih Azık, and Betül Tavil, and Serap Teber, and Bahattin Tunç, and Duygu Uçkan
Levetiracetam-Associated Psychogenic Non-epileptic Seizures; A Hidden Paradox.
July 2018, Journal of population therapeutics and clinical pharmacology = Journal de la therapeutique des populations et de la pharmacologie clinique,
Arzu Yazal Erdem, and Fatih Azık, and Betül Tavil, and Serap Teber, and Bahattin Tunç, and Duygu Uçkan
Epileptic seizures caused by low valproic acid levels from an interaction with meropenem.
August 2006, Journal of clinical pharmacy and therapeutics,
Arzu Yazal Erdem, and Fatih Azık, and Betül Tavil, and Serap Teber, and Bahattin Tunç, and Duygu Uçkan
Renal tubular dysfunction in epileptic children on valproic acid therapy.
March 2001, Pediatric nephrology (Berlin, Germany),
Arzu Yazal Erdem, and Fatih Azık, and Betül Tavil, and Serap Teber, and Bahattin Tunç, and Duygu Uçkan
Levetiracetam in the Treatment of Epileptic Seizures After Liver Transplantation.
September 2015, Medicine,
Arzu Yazal Erdem, and Fatih Azık, and Betül Tavil, and Serap Teber, and Bahattin Tunç, and Duygu Uçkan
Valproic Acid-induced Hyperammonemic Encephalopathy Promoted by Levetiracetam.
December 2014, Journal of epilepsy research,
Copied contents to your clipboard!